timothy sykes logo
Haemonetics (HAE) Stock Climbs As Analysts Hike Targets Thumbnail
G Google News

Haemonetics (HAE) Stock Climbs As Analysts Hike Targets

ELLIS HOBBS•UPDATED AUG. 18, 2026, 3:03 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Haemonetics Corporation stocks have been trading up by 17.07 percent after strong earnings and guidance boosted investor confidence.

Key Takeaways

  • Fiscal Q1 results from Haemonetics beat expectations on EPS and revenue, with strength across Plasma, Blood Management Technologies, and Interventional Technologies, plus a full-year guidance raise.
  • The company posted fiscal Q1 adjusted EPS of $1.14 versus the $0.87 FactSet consensus, a sizable upside surprise.
  • Fiscal Q1 net revenue reached $339.4M, above the $327.9M estimate, highlighting stronger demand.
  • Haemonetics modestly raised FY27 revenue and EPS growth outlooks to 5%-8%, signaling higher long-term confidence.
  • After the beat, Bank of America, Raymond James, Baird, Barrington, and Citi all lifted price targets on HAE, with most reiterating Buy or Outperform.

Candlestick Chart

Live Update At 15:02:40 EDT: On Tuesday, August 18, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 17.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, HAE has flipped from slow grinder to momentum name over the past few weeks. After consolidating in the high-$70s to low-$80s through 2026/07/24, Haemonetics started pushing higher, breaking into the mid-$80s by 2026/07/31 and holding those gains into early August.

The real move came after HAE’s fiscal Q1 earnings beat. The stock jumped from a close near $91 on 2026/08/12 to an intraday high above $106.80 on 2026/08/18, with the latest daily close at $105.68. That’s a roughly 20%-plus run from the 2026/07/24 close of $78.78, a strong trend for a mid-cap medtech.

Intraday, the 5‑minute chart shows Haemonetics trading cleanly between $104 and $106 for most of the afternoon, with tight ranges and minimal breakdowns. That tells traders dip buyers are stepping in quickly and shorts are not in control.

More Breaking News

Fundamentally, HAE is priced like a quality growth story. A price‑to‑earnings ratio near 44 and price‑to‑sales around 3.1 signal traders are paying up for earnings momentum and a nearly 59% gross margin. At the same time, leverage is manageable, with a current ratio of 3.1 and interest coverage above 21x, which gives Haemonetics room to ride out volatility while it executes its plan.

Why Traders Are Watching HAE Right Now

The core story for Haemonetics is simple: strong execution plus rising expectations. HAE delivered fiscal Q1 adjusted EPS of $1.14, far ahead of the $0.87 consensus. Net revenue landed at $339.4M versus $327.9M expected. That’s not just bottom‑line engineering; that’s real top‑line outperformance. Management also called out share gains in Plasma, ongoing momentum in Blood Management Technologies, and a return to growth in Interventional Technologies. For traders, that’s multiple engines firing at once.

On top of the quarter, Haemonetics nudged its long‑term FY27 targets higher, taking both revenue and adjusted EPS growth outlooks up to 5%-8% from 4%-7%. It’s not a moonshot, but it is a clear signal: management sees the path and is comfortable tightening the screws on expectations.

The Street has responded fast. Bank of America raised its HAE target from $93 to $100 and reiterated a Buy after hosting the CEO, saying Haemonetics can deliver best‑in‑class performance and drive a valuation rerating by FY27. Raymond James went even further, bumping its target from $90 to $105 with an Outperform rating, while Baird lifted its target from $88 to $96, also at Outperform, after what it called a larger‑than‑expected Q1 beat and guidance raise.

Barrington Research raised its Haemonetics target to $95 from $89 and stayed Outperform, pointing to improving profitability and the potential to reduce debt by fiscal 2027. Citi is the cautious voice, moving its target from $79 to $92 but sticking with a Neutral stance, a reminder that not every desk is ready to chase. Even so, BofA Securities notes HAE now sits with an overweight profile and a consensus target near $96.90, below current trading levels, which tells day traders and swing traders that the stock has already run ahead of average models.

Conclusion

For traders, the tension in HAE is exactly what creates opportunity. On one side, you have a textbook growth setup: Haemonetics beats on EPS and revenue, posts year‑over‑year growth, raises long‑term guidance, and gets a wall of higher price targets. On the other, you see moments where the stock trades flat to slightly lower premarket despite those beats, hinting at profit‑taking and expectations that were already high.

Technically, Haemonetics has broken out of its $80s base and is holding above $100 with tight intraday action. That’s the kind of behavior momentum traders look for when deciding whether to buy dips or fade strength. Fundamentally, HAE throws off solid cash flow, with about $52.3M in operating cash in the latest quarter and roughly $44.4M in free cash flow, even after capital spending and debt paydown. Debt remains elevated, but multiple analysts now see a clear path to balance‑sheet improvement by 2027.

The key is discipline. As Tim Sykes always stresses, “Cut losses quickly and don’t marry a stock — respect the price action first.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” That mindset applies directly to trading a name like HAE after a strong move — taking singles and managing risk instead of swinging for home runs. Haemonetics has earned traders’ attention with real numbers and real guidance, not hype. But the job for anyone trading HAE now is to respect how far it’s moved, watch the levels, and let the chart confirm whether this breakout has another leg or is due for a healthy pullback. This analysis is for educational and research purposes only and should never be taken as investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”